NeuroBo Pharmaceuticals, Inc. (NRBO)

3.1000 +0.0800 (+2.65%) At close: 04:00PM EDT

NeuroBo Pharmaceuticals, Inc.

200 Berkeley Street
Office 19th Floor
Boston, MA 02116
United States
857 702 9600
https://www.neurobopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Hyung-Heon Kim	CEO, President, Principal Executive & Director	625.16k	N/A	1975
Mr. Marshall H. Woodworth	CFO, Principal Financial Officer & Principal Accounting Officer	154.5k	N/A	1958
Dr. Mi-Kyung Kim	Chief Scientific Officer	N/A	N/A	N/A
Mr. Robert Homolka	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Corporate governance

NeuroBo Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.